Shares of Infinity Pharmaceuticals Inc. dropped 40 percent Friday on news that the biotech is stopping development of Hedgehog inhibitor saridegib (IPI-926) in pancreatic cancer after interim data from a Phase II trial showed better survival in the placebo arm.